Archive

Posts Tagged ‘Vaccine’

Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares

August 14th, 2009 admin No comments

CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.

EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.

Reblog this post [with Zemanta]
Categories: Advisory Board, Anthrax Vaccine, BioThrax, El-Hibri Fuad, Emergent BioSolutions, Entrepreneur of the Year, FDA, Food and Drug Administration, Fuad El-Hibri, Fuad Elhibri, Hepatitis B Vaccine, Shareholders, Typhoid Vaccine Tags: , , , , , , ,

Emergent Biosolutions El-Hibri

June 22nd, 2009 admin No comments

Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock:

On January 20, 2009, Emergent Biosolutions announces that Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock: 13.5 million shares had been issued to date with 47% controlled by Fuad El-Hibri. It also announced Stage II testing of vaccines for Typhoid, Hepatitis B, and Tuberculosis.

Reblog this post [with Zemanta]
Categories: Answer.com, BioThrax, El-Hibri Foundation, El-Hibri Peace Education, El-Hibri Peace Education Prize, Emergent BioSolutions, Entrepreneur of the Year, Fuad El-Hibri, Fuad Elhibri, Ibrahim Y. El-Hibri, Profits and Losses, Shareholders, Tuberculosis Vaccine, W. James Jackson, Washington DC, Washington Gala Tags: , , , , , , , ,

Tuberculosis Vaccine by Fuad El-Hibri

June 21st, 2009 admin No comments
The search for a new TB vaccine is a complex and challenging process requiring a broad commitment, and we are pleased to be collaborating with so many dedicated and talented researchers on this important effort:

Tuberculosis Vaccine by Fuad El-Hibri

Fuad El-Hibri’s EBS is Developing TB Vaccine

Jun 15
Comments

Fuad El-Hibri’s EBS is Developing TB Vaccine

“The search for a new TB vaccine is a complex and challenging process requiring a broad commitment, and we are pleased to be collaborating with so many dedicated and talented researchers on this important effort,” said Jerald C. Sadoff, president and CEO of Aeras, in a statement.

“This marks an important milestone in what we believe is an extraordinary opportunity to prevent tuberculosis, which is a major global health crisis. Emergent is proud to join such distinguished partners as we make progress in the fight against one of the world’s deadliest diseases,” said Fuad El-Hibri, chairman and CEO of Rockville biotech Emergent BioSolutions, which is teaming with the University of Oxford on the TB project.

Fuad El-Hibri Key Executive at Emergent

Reblog this post [with Zemanta]
Categories: Emergent BioSolutions, Fuad El-Hibri, Tuberculosis Vaccine Tags: , , , , , , ,

Fuad El-Hibri’s Emergent BioSolutions’ Typhoid Vaccine

June 21st, 2009 admin No comments

We are very pleased to have met the objectives of this Phase II study of our typhoid vaccine candidate:

Fuad El-Hibri’s Emergent BioSolutions‘ Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study

“We are very pleased to have met the objectives of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine. We are particularly grateful to the Wellcome Trust for their partnership and generous support of this important project,” stated Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Typhoid is endemic in many developing countries, putting countless international travelers and families who visit these nations at risk. With typhoid claiming 200,000 lives each year, continued progress in the development of this vaccine is an important milestone in our company’s efforts to protect life. Emergent BioSolutions remains committed to addressing significant underserved health needs,” he continued.

About the Typhoid Vaccine Candidate

The company’s typhoid vaccine candidate is a live, attenuated strain of the Salmonella typhi bacterium designed to eliminate virulence by deletion of two specific genes. The vaccine is intended to be administered in a single, drinkable dose prior to travel to countries where typhoid is endemic. If approved, this method of administration could provide a competitive advantage compared to currently approved typhoid vaccines.

Fuad El-Hibri EBS Typhoid Vaccine

Jun 15
Comments

Fuad El-Hibri EBS Typhoid Vaccine

Emergent BioSolutions is on the path to finding gold with its typhoid vaccine following positive results in a Phase II trial.

The Maryland-based biopharmaceutical company is developing a single-dose oral drinkable typhoid vaccine aimed to take on Crucell’s three to four dose oral formulation and Sanofi’s injectable formulation. The global travellers market was worth $130m (€92m) in 2003, and is expected to increase to $200m by 2014.

According to the company, the typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity with an overall immune response rate of greater than 50 per cent, with 95 per cent confidence.

“We are very pleased to have met the objective of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine,” Emergent BioSolutions chairman and chief executive Fuad El-Hibri said.

“Typhoid is endemic in many developing countries, putting countless international travellers and families who visit these nations at risk. With typhoid claiming 200,000 lives each year, continued progress in the development of this vaccine is an important milestone in our company’s efforts to protect life.”

The company’s typhoid vaccine candidate is a live, attenuated strain of the Salmonella typhi bacterium designed to eliminate virulence by deletion of two specific genes.

Reblog this post [with Zemanta]
Categories: El-Hibri Fuad, Emergent BioSolutions, Fuad El-Hibri, Fuad Elhibri, Typhoid Vaccine Tags: , , , , , , ,